Elsevier

Vaccine

Volume 20, Issues 19–20, 7 June 2002, Pages 2500-2507
Vaccine

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

https://doi.org/10.1016/S0264-410X(02)00180-9Get rights and content

Abstract

We present data to confirm that exposure to varicella boosts immunity to herpes-zoster. We show that exposure to varicella is greater in adults living with children and that this exposure is highly protective against zoster (Incidence ratio=0.75, 95% CI, 0.63–0.89). The data is used to parameterise a mathematical model of varicella zoster virus (VZV) transmission that captures differences in exposure to varicella in adults living with and without children. Under the ‘best-fit’ model, exposure to varicella is estimated to boost cell-mediated immunity for an average of 20 years (95% CI, 7–41years). Mass varicella vaccination is expected to cause a major epidemic of herpes-zoster, affecting more than 50% of those aged 10–44 years at the introduction of vaccination.

Introduction

Primary infection with varicella zoster virus (VZV) results in varicella (chickenpox) after which the virus becomes latent in dorsal root ganglia and may reactivate decades later, as a result of waning cell-mediated immunity, to cause herpes-zoster (shingles) [1]. Zoster is mostly suffered by the elderly and is the cause of significant morbidity [2]. Hope–Simpson first hypothesized that exposure to varicella reduces the risk of reactivation by boosting specific immunity to the virus (exogenous boosting) [1]. This hypothesis has yet to be supported by strong epidemiological evidence.

A live attenuated VZV (Oka) vaccine was developed by Takahashi et al. in the beginning of the 1970s [3], and was introduced into the routine infant immunization schedule of the US in 1995 [4]. On account of the strong evidence in favour of varicella vaccination [5], [6], [7], [8], [9], its introduction is imminent in many countries. However, one potential danger of varicella immunisation is often neglected. If exposure to VZV reduces the rate of reactivation, then reduction of varicella cases after mass vaccination could increase the incidence of zoster [10], [11], [12], [13], [14], leading to adverse public health consequences [12], [13], [15]. Here, we present convincing data in support of this hypothesis. We use these data to parameterise a mathematical model of VZV transmission which is used to estimate the impact of mass vaccination on the incidence of zoster.

Section snippets

Data

Data were taken from the fourth National Survey of Morbidity in General Practice (MSGP4), a survey of general practices covering a 1% sample (over 500,000 patients) of England and Wales during 1991/92 [16]. Details of all consultations were recorded during the study year, along with socio-economic information on the patients [16]. For children under 16 years, all first episodes of varicella and zoster were included in the analysis. For adults, first episodes of varicella and zoster were

Results

The overall age-specific incidence of zoster observed in the MSGP4 study was similar to other industrialised countries [17], [19]. Here, we present the age-specific annual incidence rate of zoster in England and Wales by household exposure to children (Fig. 2a). Living with children was found to be significantly protective against zoster (P<0.001) with an incidence ratio of 0.75 (95% CI, 0.63–0.89). There was no evidence of confounding by sex, ethnicity or socio-economic class (a range of

Discussion

We present strong epidemiological evidence supporting the hypothesis that exposure to varicella inhibits herpes-zoster. Primarily, our analysis shows that exposure to varicella is greater in adults living with children and that this exposure is highly protective against zoster. We further estimate that the average period of immunity conferred by exposure to varicella is 20 years. Previously, only indirect evidence has supported the hypothesis that re-exposure to VZV offers protection against

Acknowledgements

The United Kingdom Medical Research Council, Grant number G9818303, provided financial support. We thank Dr Elizabeth Miller for comments on the manuscript. The MSGP4 data are Crown Copyright and are reproduced with permission.

References (26)

  • M. Vazquez et al.

    The effectiveness of the varicella vaccine in clinical practice

    N. Engl. J. Med.

    (2001)
  • D.A. Clements et al.

    Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina

    Arch. Pediatr. Adolesc. Med.

    (2001)
  • J.F. Seward et al.

    Varicella disease after introduction of varicella vaccine in the United States, 1995–2000

    JAMA

    (2002)
  • Cited by (0)

    View full text